Whanin Pharmaceutical is a leading South Korean manufacturer specializing in prescription medications. The company is recognized as a leader in the psychiatric and mental health treatment sector, holding a dominant position in the CNS (central nervous system) pharmaceutical market with a focus on antidepressants, schizophrenia treatments, and epilepsy therapies. Whanin Pharmaceutical's key products include psychiatric medications, cognitive function enhancers, and dementia treatments. Notable active ingredients in their portfolio include Quetiapine, Donepezil, Oxiracetam, Rivastigmine, and Memantine.

Our core research direction focuses on the development of innovative new medication through C&D (Connect & Development). The company focuses its capacities in developing innovative new medications not only in its main field of CNS but also over the entire sphere of health care, by adopting products, original technologies and ideas through multiple joint ventures and academic collaboration, and selecting and verifying lead compound using cutting-edge Risk Management system. Generics and Incrementally Modified Drugs Sectors are also contributing to our growth as a pharmaceutical company with rapid product development and competitiveness in entry into the global market through active coordination with overseas platforms, commercialization technologies with competitiveness in the global market and advanced GxP level CDMO, based on active R&D investment with Open Innovation.

Public

Pharma